Navigation Links
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
Date:2/23/2011

HORSHAM, Pa., Feb. 23, 2011 /PRNewswire/ -- Centocor Ortho Biotech Inc. (Centocor) today received a decision from the Court of Appeals for the Federal Circuit in Washington, D.C. overturning a 2009 federal court jury verdict that awarded the company $1.8 billion after finding Abbott Laboratories liable for patent infringement.

A panel of the court ruled that the patent relating to Centocor anti-tumor necrosis factor (TNF) -alpha rheumatoid arthritis treatments was invalid.

"We are disappointed by the decision," said Rob Bazemore, president of Centocor Ortho Biotech Inc.  "We are considering whether to ask for reconsideration by the panel or by the court of appeals as a whole."

The original verdict was returned in June 2009 by a U.S. District Court jury in Marshall, Texas.  The patent is co-owned by New York University and Centocor, the exclusive licensee.

About Centocor Ortho Biotech Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology, and oncology. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care. For more information about Centocor Ortho Biotech, visit www.CentocorOrthoBiotech.com.  Centocor Ortho Biotech Inc. is a wholly owned subsidiary of Johnson & Johnson (NYSE: JNJ).

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Centocor Ortho Biotech Inc. and/or Johnson & Johnson. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.


'/>"/>
SOURCE Centocor Ortho Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
3. Pharma CI Conference Amy Yueh Pays $52,000 to Apaporis LLC to Satisfy Judgment Against Her In Superior Court Of New Jersey Case
4. Montana Supreme Court Decision Endangers Most Vulnerable Citizens
5. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
6. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
7. CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures
8. Texas Court Asked to Appoint Receiver for Key Subsidiary of TSX Listed Northstar Healthcare, Inc. (TSX NHC) on Claims of Mismanagement and Breach of Fiduciary Duty
9. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
10. Appellate Court Decides in Favor of Fenwal
11. CRESTOR® Patent Upheld By US Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Walgreens has committed to provide ... and Washington, D.C. as part of ... was commended by shareholder advocacy organization As You Sow. ... Sow. "Many people hold on to unneeded drugs because they ... tragic consequences." --> Conrad MacKerron , Senior ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 ... of new health technologies, announced today " 10 Year ... in health tech over the past ten years.   ... nearly a decade, Health 2.0 has served as the ... and connected with thousands of technologies, companies, innovators, and ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  NOIT™ Research ... a special "Gift of Change" campaign to assist needy ... For every such unit sold between February 10, 2016 ... unit to a needy family. The NOIT is an ... non/limited-verbal autistic individuals develop language skills. ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... Florida Hospital presents Heart Health Awareness night on Sunday February 14th, as ... The puck drops at 6:00pm, but fans will have the opportunity to experience the ... The MEGA Heart will be located on Ford Thunder Alley and provide fans with ...
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY 2017 ... but would shift more of the cost burden to military beneficiaries. , MOAA’s ... in the defense budget as including limited quantifiable benefit fixes mixed with numerous beneficiary ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... discuss how to improve care by making data on heart procedures public and ... Summit on Transparency and Public Reporting of Pediatric and Congenital Heart Disease Outcomes ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
(Date:2/11/2016)... ... 11, 2016 , ... "What holds you back from ... a question as a challenge for his readers to examine the full scale ... (published by Partridge Singapore), Clarke explores the subject with more depth, revealing time-honored ...
Breaking Medicine News(10 mins):